

RESEARCH

Open Access



# Dietary protein intake and mortality among survivors of liver cirrhosis: a prospective cohort study

Ghazal Daftari<sup>1</sup>, Asal Neshatbini Tehrani<sup>2,3</sup>, Fereshteh Pashayee-khamene<sup>4</sup>, Sara Karimi<sup>4</sup>, Saleheh Ahmadzadeh<sup>4</sup>, Azita Hekmatdoost<sup>4</sup>, Amin Salehpour<sup>5</sup>, Mahdi Saber-Firoozi<sup>6</sup>, Behzad Hatami<sup>7</sup> and Zahra Yari<sup>8\*</sup>

## Abstract

**Background** Liver cirrhosis is a worldwide burden and is associated with poor clinical outcomes, including increased mortality. The beneficial effects of dietary modifications in reducing morbidity and mortality are inevitable.

**Aim** The current study aimed to evaluate the potential association of dietary protein intake with the cirrhosis-related mortality.

**Methods** In this cohort study, 121 ambulatory cirrhotic patients with at least 6 months of cirrhosis diagnosis were followed-up for 48 months. A 168-item validated food frequency questionnaire was used for dietary intake assessment. Total dietary protein was classified as dairy, vegetable and animal protein. We estimated crude and multivariable-adjusted hazard ratios (HRs) with 95% confidence intervals (CIs), applying Cox proportional hazard analyses.

**Results** After full adjustment for confounders, analyses showed that total (HR = 0.38, 95% CI = 0.2–1.1, *p* trend = 0.045) and dairy (HR = 0.38, 95% CI = 0.13–1.1, *p* trend = 0.046) protein intake was associated with a 62% lower risk of cirrhosis-related mortality. While a higher intake of animal protein was associated with a 3.8-fold increase in the risk of mortality in patients (HR = 3.8, 95% CI = 1.7–8.2, *p* trend = 0.035). Higher intake of vegetable protein was inversely but not significantly associated with mortality risk.

**Conclusion** A comprehensive evaluation of the associations of dietary protein intake with cirrhosis-related mortality indicated that a higher intakes of total and dairy protein and a lower intakes of animal protein are associated with a reduced risk of mortality in cirrhotic patients.

**Keywords** Protein, Dairy, Cirrhosis, Mortality, Cohort study

\*Correspondence:

Zahra Yari  
zahrayari\_nut@yahoo.com

<sup>1</sup> School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

<sup>2</sup> Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

<sup>3</sup> Department of Nutrition, School of Allied Medical Sciences, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

<sup>4</sup> Clinical Nutrition and Dietetics Department, Faculty of Nutrition Sciences and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences Tehran, Tehran, Iran

<sup>5</sup> Occupational Health Research Center, School of Public Health, Iran University of Medical Science, Tehran, Iran

<sup>6</sup> Digestive Disease Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran

<sup>7</sup> Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran

<sup>8</sup> Department of Nutrition Research, National Nutrition and Food Technology Research Institute and Faculty of Nutrition Sciences and Food Technology, Shahid Beheshti University of Medical Sciences Tehran, West Arghavan St. Farahzadi Blvd., Sharake Qods, Tehran, Iran



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

## Introduction

Liver cirrhosis is the first cause of liver-related mortality and morbidity globally with an annual exceeding mortality rate [1]. About one million deaths worldwide are reported every year due to cirrhosis which can be prevented [1]. The Global Burden of disease project in 2017 reported that 1.42% of all deaths in Iran were due to cirrhosis and liver-related disorders [2]. Cirrhosis is defined by progressive liver damage resulting in transformed lobular architecture and lowered functional capacity [3]. Infections, hepatitis B and C, non-alcoholic fatty liver disease (NAFLD), metabolic syndrome and alcohol are etiologic factors of cirrhosis [4]. Cirrhosis complications are various from no symptoms in the compensated state to nausea, ascites and loss of appetite in mild cirrhosis and sarcopenia, spontaneous bacterial peritonitis, variceal bleeding, renal failure and hepatic encephalopathy in advanced stages [5].

Dietary therapy plays a major role in reversing the progression of liver cirrhosis and nutritional evaluation aims to reduce morbidity and mortality by exploring modifiable nutritional risk factors [6]. The liver is the central core of fat, protein and carbohydrate metabolism, thus it is predictable that liver cirrhosis may result in protein energy malnutrition (PEM) [7]. PEM is directly related to survival in cirrhosis and its prevalence varies from relatively 60% in decompensated and 20% in compensated cirrhotic patients [8]. Protein sources such as animal, dairy and vegetable may have different impacts on cirrhosis and are recommended to prevent sarcopenia and improve nitrogen balance [9].

According to the European Society of Clinical Nutrition and Metabolism (ESPEN), the daily recommended intake of protein in cirrhotic patient is 1.2 to 1.5 g/kg body weight [9]. Reduced skeletal muscle volume and plasma albumin level are the indicators of muscular and visceral protein loss, respectively [10]. Analyzing the plasma amino acids in cirrhosis indicates decreased branched-chain amino acids (BCAAs) and increased aromatic amino acids (AAAs) [7, 10]. BCAAs are used to detoxify ammonia and energy production [10]. Vegetables and dairy products are rich in BCAAs, which can improve physical and mental status, regulate protein imbalance, regenerate hepatic cells, increase albumin levels and reinforce immune system [10–12].

Considering previous studies, higher protein intake was associated with lower morbidity and all-cause mortality in various diseases [13–15]. However, little is known about dietary protein intake and cirrhosis-related mortality. In a current prospective cohort study, we aimed to evaluate the association between dietary total, animal, vegetable and dairy protein intake with cirrhosis-related mortality.

## Methods and materials

### Study population

In this cohort study, 166 ambulatory cirrhotic patients who had been diagnosed for at least 6 months were recruited from two educational hospitals, in Tehran, Iran. The participants were enrolled from 2016 to 2018 and were followed up until 30 April 2022. Exclusion criteria included the following: having renal failure, malignancies, diabetes mellitus, infectious diseases, cardiac disease, acquired immune deficiency syndrome, pancreatic insufficiency and being pregnant or lactating. Also, we excluded participants (n=45) with a cancer diagnosis in the first year, missing or incomplete general lifestyle or dietary information, taking high or low energy (< 500 or > 5000 kcal/day) and extreme body mass index (BMI) (< 15 or > 50 kg/m<sup>2</sup>). In total, 121 participants (38 women

**Table 1** Characteristics of participants

| Variable                                  | Mean ± SD   | %  |
|---|-------------|----|
| Age                                       | 54.8 ± 11.9 |    |
| Male                                      |             | 68 |
| Etiology of cirrhosis                     |             |    |
| Virus                                     |             | 56 |
| Autoimmune                                |             | 31 |
| Other                                     |             | 13 |
| MELD score                                | 12.2 ± 4.9  |    |
| Child Pugh category (A/B/C)               |             |    |
| A   |             | 69 |
| B & C                                     |             | 31 |
| Alcohol drinker                           |             | 23 |
| Smoker, %                                 |             | 39 |
| Subjective global assessment (A/B/C)      |             |    |
| A   |             | 32 |
| B   |             | 54 |
| C   |             | 14 |
| Dynapenia                                 |             | 47 |
| Dry weight, kg                            | 73.9 ± 16.4 |    |
| Height, cm                                | 165.4 ± 8.3 |    |
| BMI, kg/m <sup>2</sup>                    | 27.1 ± 5.3  |    |
| Calorie intake (Kcal/day)                 | 2123 ± 649  |    |
| Protein intake (g/day)                    | 78 ± 27     |    |
| Protein intake (% of energy)              | 14 ± 2      |    |
| Protein intake, g/kg estimated dry weight | 1.2 ± 0.5   |    |
| < 0.8 g/kg (very low protein intake)      |             | 21 |
| 0.8–1.2 g/kg (low protein intake)         |             | 34 |
| > 1.2 g/kg (target protein intake)        |             | 45 |
| Dairy protein (g/day)                     | 27 ± 24     |    |
| Vegetable protein (g/day)                 | 13 ± 9      |    |
| Animal protein (g/day)                    | 26 ± 16     |    |

Values are means ± SDs for continuous variables and percentages for categorical variables

and 83 men) remained for the analyses. Participants received annual telephone calls during which follow-up questionnaires were completed regarding the occurrence of death or any medical event.

The protocol of this study was approved by National nutrition and Food Technology Research Institute (NNFTRI) ethics committee (Ir.sbmunnftri.1396.186.). All participants were informed about the study and written consent forms were obtained.

### Dietary assessment

Dietary intakes of participants were collected using a reliable and valid food frequency questionnaire (FFQ) including 168 items through face-to-face interview [16]. During the interview, trained dietitians explained serving and typical portion sizes for each food item to participants, and then asked about the number of times each item was taken in the past year. Monthly, weekly and daily consumption of each food was documented and converted to grams based on household measurements [17, 18]. We used Nutritionist IV software to analyze dietary data. Energy and nutrient content were calculated using The United States Department of Agriculture (USDA) food composition table (FCT). In addition to

total protein, the intakes of dairy, vegetable and animal protein were calculated and reported as gram per day.

### Potential confounders

Participants' data including age, gender, alcohol consumption, smoking, subjective global assessment tool (SGA), Child–Pugh score, Model for end-stage liver disease (MELD) and etiology of cirrhosis were collected. A digital scale to the nearest 100 g and a portable stadiometer to the nearest 1 cm were applied to measure the weight and height of the participants with minimal clothes and without shoes, respectively. BMI was calculated by dividing the weight in kilograms by the square of the height in meters. SGA based on Destky et al. study [19] was recorded. Considering this assessment, participants were divided into three groups: A: well-nourished, B: moderately malnourished and C: severely malnourished. Severity and prognosis of liver cirrhosis were evaluated by Child–Pugh and MELD scores [17]. Prothrombin time, serum bilirubin, serum albumin, presence of hepatic encephalopathy and ascites are used to calculate Child–Pugh score by which the patients were classified into three groups.

Muscle strength was assessed based on hand grip strength in the dominant hand using a hydraulic hand

**Table 2** Characteristics of participants classified according to dynapenia and obesity classifications

|                              | Dynapenic obese     | Nondynapenic obese | Dynapenic non-obese     | Nondynapenic non-obese |
|------------------------------|---------------------|--------------------|-------------------------|------------------------|
| Prevalence (%)               | 36                  | 37                 | 22                      | 26                     |
| No. of deaths                | 19                  | 6                  | 10                      | 8                      |
| Male, %                      | 56                  | 73                 | 64                      | 66                     |
| Age                          | 56 ± 11             | 55 ± 9             | 62 ± 12                 | 48 ± 13 <sup>‡</sup>   |
| MELD score                   | 14 ± 6 <sup>†</sup> | 10 ± 3             | 14 ± 7 <sup>†</sup>     | 12 ± 4                 |
| Child Pugh category          |                     | *                  |                         |                        |
| A                            | 42                  | 85                 | 60                      | 74                     |
| B & C                        | 58                  | 15                 | 40                      | 26                     |
| Alcohol drinker, %           | 22                  | 37                 | 12 <sup>†</sup>         | 25                     |
| Smoker, %                    | 31                  | 56                 | 28                      | 43                     |
| Subjective global assessment |                     |                    | †                       |                        |
| A                            | 28                  | 50                 | 11                      | 27                     |
| B                            | 56                  | 44                 | 61                      | 59                     |
| C                            | 16                  | 6                  | 28                      | 14                     |
| BMI, kg/m <sup>2</sup>       | 29 ± 4              | 31 ± 4             | 21 ± 1 <sup>†*</sup>    | 22 ± 2 <sup>†*</sup>   |
| Calorie intake (Kcal/day)    | 1763 ± 576          | 2539 ± 586*        | 1835 ± 594 <sup>†</sup> | 2217 ± 682*            |

Values are means ± SDs for continuous variables and percentages for categorical variables

ANOVA for quantitative variables and  $\chi^2$  test for qualitative variables

\*  $P < 0.05$  versus dynapenic obese

†  $P < 0.05$  versus nondynapenic obese

‡  $P < 0.05$  versus dynapenic non-obese

Obese: BMI > = 25

dynamometer (Exacta, North Coast Medical, Gilroy, USA). Low muscle strength was considered as a hand grip strength less than 26 kg for men and less than 18 kg for women [20] and consequently dynapenia was determined [21].

**Statistical analysis**

Participants were divided into three groups based on their dietary protein intake. Also, according to BMI and dynapenia, participants were assigned in one of the following four groups: dynapenic obese, nondynapenic obese, dynapenic non-obese and nondynapenic non-obese. Basic characteristics of patients were compared using chi-squared ( $\chi^2$ ) test for categorical variables and one-way analysis of variance (ANOVA) test for continuous variables. We used Cox proportional hazards regression models for cirrhotic-related mortality associated with the dietary total, dairy, vegetable and animal

protein intake to estimate 95% confidence intervals (CIs) and multivariable-adjusted hazard ratios (HRs). Potential confounders were defined in the following series: Model 1: adjusted for sex (male, female) and age (continuous); Model 2: additionally adjusted for BMI (continuous), energy intake (continuous), alcohol use (yes, no) and smoking (yes, no); and Model 3: additionally adjusted for Child–Pugh (A, B & C), MELD (continuous) and etiology (virus, autoimmune, other). In relation to risk of mortality, we used the likelihood ratio test (LRT) to assess potential interactions between important risk factors at baseline such as age, BMI, MELD, Child–Pugh and SGA and intake of total, dairy, animal and vegetable protein. From the date of participation until censoring on 30 April 2022 or lost to follow-up or date of death, whichever occurred first was considered as person-years of follow-up. Statistical analyses were conducted using SPSS (version 19; SPSS Inc, Chicago, IL, USA) and  $P < 0.05$  was set as statically significant.

**Table 3** Hazard ratios for total mortality, according to the protein intake tertile

|                              | Tertiles of dietary protein intake (g/day) |                  |                  | P trend |
|------------------------------|--|------------------|------------------|---------|
| <b>Total protein (g/day)</b> | T1 (< 63)                                  | T2 (63–89)       | T3 (89 <)        |         |
| No. of deaths                | 20   | 17               | 6                |         |
| Model 1                      | ref  | 0.93 (0.45–1.9)  | 0.33 (0.12–0.87) | 0.031   |
| Model 2                      | ref  | 0.88 (0.3–2.5)   | 0.45 (0.1–2.05)  | 0.028   |
| Model 3                      | ref  | 0.78 (0.2–3.5)   | 0.38 (0.2–1.1)   | 0.045   |
|                              | Tertiles of dietary protein intake (g/kg)  |                  |                  | P trend |
| <b>Total protein (g/kg)</b>  | T1 (< 0.9)                                 | T2 (0.9–1.4)     | T3 (1.4 <)       |         |
| No. of deaths                | 20   | 17               | 6                |         |
| Model 1                      | ref  | 0.48 (0.24–0.98) | 0.37 (0.16–0.83) | 0.002   |
| Model 2                      | ref  | 0.5 (0.2–1.14)   | 0.32 (0.1–1)     | 0.021   |
| Model 3                      | ref  | 0.68 (0.14–3)    | 0.45 (0.1–2.4)   | 0.003   |
| <b>Dairy protein</b>         | T1 (< 11)                                  | T2 (11–32)       | T3 (> 32)        |         |
| No. of deaths                | 20   | 13               | 10               |         |
| Model 1                      | ref  | 0.3 (0.13–0.69)  | 0.32 (0.14–0.7)  | 0.024   |
| Model 2                      | ref  | 0.5 (0.2–1.4)    | 0.6 (0.2–1.7)    | 0.098   |
| Model 3                      | ref  | 0.45 (0.2–1.04)  | 0.38 (0.13–1.1)  | 0.046   |
| <b>Vegetable protein</b>     | T1 (< 7)                                   | T2 (7–16)        | T3 (> 16)        |         |
| No. of deaths                | 20   | 12               | 11               |         |
| Model 1                      | ref  | 0.5 (0.23–1.05)  | 0.47 (0.2–1.03)  | 0.022   |
| Model 2                      | ref  | 0.85 (0.3–2.4)   | 0.6 (0.2–1.5)    | 0.398   |
| Model 3                      | ref  | 0.65 (0.2–1.8)   | 0.58 (0.13–2.6)  | 0.633   |
| <b>Animal protein</b>        | T1 (< 15)                                  | T2 (15–33)       | T3 (> 33)        |         |
| No. of deaths                | 10   | 15               | 18               |         |
| Model 1                      | ref  | 1.4 (0.6–3.2)    | 1.4 (0.6–3.3)    | 0.207   |
| Model 2                      | ref  | 2.6 (0.9–6.8)    | 2.3 (0.9–5.9)    | 0.021   |
| Model 3                      | ref  | 2.9 (1.4–5.9)    | 3.8 (1.7–8.2)    | 0.035   |

Cox proportional hazards regression models for estimating HRs and 95% CIs

Model 1: adjusted for age and sex

Model 2: additionally adjusted for energy intake, BMI, smoking, alcohol


Model 3: additionally adjusted for etiology, MELD and child

**Results**

Characteristics of participants are shown in Table.1. At the baseline the mean age ± standard deviation (SD) of patients was 54.8 ± 11.9 years. Overall, 68% of participants were men and the etiology in 56% of cirrhotic patients was viral hepatitis. In 3955 person-month of follow-up, 43 deaths (36 men and 7 women) occurred. Liver failure was responsible for 47% of deaths, cardiovascular diseases 40%, carcinoma 3% and other causes for 10% of deaths. The mean of total energy and energy-adjusted protein intake of patients was 2123 kcal and 78 g, respectively. On average, intake of total, dairy, vegetable and animal protein was 27, 13 and 26 g per

day, respectively. The mean BMI of participants was 27.1 kg/m<sup>2</sup> and relatively half of patients (47%) were dynapenic. Smoking in 39% and alcohol intake in 23% of participants were reported.

Characteristics of participants according to dynapenia and obesity classifications are shown in Table 2. Based on SGA, the prevalence of malnutrition was significantly higher in non dynapenic obese patients than in dynapenic non-obese patients. Also, the severity of the disease in dynapenic patients was more severe than non-dynapenic patients, based on MELD score. Comparison of non-obese patients showed that the mean age of those with dynapenia is significantly higher than non-dynapenic



**Fig. 1** Multivariate hazard ratios of total protein intake tertiles for cirrhosis-related mortality according to risk factor status at baseline (Cox proportional hazards regression models for estimating HRs and 95% CIs, multivariable models were adjusted for sex, age, energy intake, BMI, smoking, alcohol, etiology, MELD and child, except for the respective stratifying factor). Data are reported as HR (95% CI). **A** obesity-dynapenia phenotypes ( $P=0.026$  for interaction); **B** SGA A vs B and C ( $P=0.056$  for interaction); **C** MELD score below median vs above median ( $P=0.239$  for interaction); **D** Child Pugh A vs B&C ( $P=0.637$  for interaction). Ref indicates reference group. BMI: body mass index, subjective global assessment tool (SGA), Model for end-stage liver disease (MELD)


patients. According to Child Pugh score, dynapenia in obese patients was significantly associated with worse prognosis of patients with cirrhosis.

Confidence intervals (CIs) and multivariable-adjusted hazard ratios (HRs) for cirrhotic-related mortality related to dietary total, animal, vegetable and dairy protein intake are shown in Table 3.

After adjusting the results for age and sex, intake of total protein, dairy and vegetable protein was significantly associated with a reduction in the risk of mortality in cirrhotic patients. In this model, protein intake was associated with a non-significant increase in mortality risk. By further adjusting the results for energy

intake, BMI, smoking and alcohol, this significance was lost for vegetable and dairy protein, but the association of animal protein intake with increased risk of mortality in cirrhosis patients became significant.

As shown in Table 3, after adjusting for all confounders, it has been found that the mortality risk of participants in the third tertile of total dietary protein intake was significantly lower than that of the first tertile (HR T3 vs T1 = 0.38, 95% CI = 0.2–1.1, P trend = 0.045). The statistical analysis of total protein, both in grams per day and in grams per weight, had similar results. Similar results were obtained for dairy protein intake. So that the risk of mortality in the third tertile was



**Fig. 2** Multivariate hazard ratios of dairy protein intake tertiles for cirrhosis-related mortality according to risk factor status at baseline (Cox proportional hazards regression models for estimating HRs and 95% CIs, multivariable models were adjusted for sex, age, energy intake, BMI, smoking, alcohol, etiology, MELD and child, except for the respective stratifying factor). Data are reported as HR (95% CI). **A** obesity-dynapenia phenotypes ( $P=0.003$  for interaction); **B** SGA A vs B and C ( $P=0.767$  for interaction); **C** MELD score below median vs above median ( $P=0.165$  for interaction); **D** Child Pugh A vs B&C ( $P=0.362$  for interaction). Ref indicates reference group. BMI: body mass index, subjective global assessment tool (SGA), Model for end-stage liver disease (MELD)




62% lower compared to the reference group (HR<sub>T3 vs T1</sub> = 0.38, 95% CI = 0.13–1.1, P trend = 0.046). It is noteworthy that higher intake of animal protein was associated with increased risk of mortality (HR<sub>T3 vs T1</sub> = 3.8, 95% CI = 1.7–8.2, P trend = 0.035). Higher intakes of vegetable protein were inversely but non-significantly associated with risk of mortality.


The association between total, dairy, vegetable and animal protein intake and risk of mortality is shown in Figs. 1, 2, 3 and 4, respectively. Higher intake of total and dairy protein significantly decreased the risk of mortality in dynapenic and severely malnourished patients. In addition, in patients with higher disease severity (MELD

score above the median >11), higher animal protein intake was significantly associated with an increased risk of mortality (HR<sub>T3 vs T1</sub> = 1.9, 95% CI = 0.7–3.9, P trend = 0.043) (Fig. 4).

The Kaplan–Meier survival curves comparing patients across tertiles of dietary protein intake are shown in Fig. 5 (A: total protein, B: dairy protein, C: vegetable protein, D: animal protein). Patients with lower dairy protein (T1) had significantly worse 4-year survival compared with patients with higher dairy protein. Comparison of the third tertile with the first tertile of total protein and vegetable protein intake also revealed a similar result, but it was not statistically significant. Higher animal protein



**Fig. 3** Multivariate hazard ratios of vegetable protein intake tertiles for cirrhosis-related mortality according to risk factor status at baseline (Cox proportional hazards regression models for estimating HRs and 95% CIs, multivariable models were adjusted for sex, age, energy intake, BMI, smoking, alcohol, etiology, MELD and child, except for the respective stratifying factor). Data are reported as HR (95% CI). **A** obesity-dynapenia phenotypes ( $P=0.026$  for interaction); **B** SGA A vs B and C ( $P=0.056$  for interaction); **C** MELD score below median vs above median ( $P=0.239$  for interaction); **D** Child Pugh A vs B&C ( $P=0.637$  for interaction). Ref indicates reference group. BMI: body mass index, subjective global assessment tool (SGA), Model for end-stage liver disease (MELD)



**Fig. 4** Multivariate hazard ratios of animal protein intake tertiles for cirrhosis-related mortality according to risk factor status at baseline (Cox proportional hazards regression models for estimating HRs and 95% CIs, multivariable models were adjusted for sex, age, energy intake, BMI, smoking, alcohol, etiology, MELD and child, except for the respective stratifying factor). Data are reported as HR (95% CI). **A** obesity-dynapenia phenotypes ( $P=0.592$  for interaction); **B** SGA A vs B and C ( $P=0.363$  for interaction); **C** MELD score below median vs above median ( $P=0.079$  for interaction); **D** Child Pugh A vs B&C ( $P=0.781$  for interaction). Ref indicates reference group. BMI: body mass index, subjective global assessment tool (SGA), Model for end-stage liver disease (MELD)

intake was associated with worse 4-year survival, but not significantly.


**Discussion**

The present cohort study showed that higher intake of dietary total protein and dairy protein and lower intake of animal protein was associated with reduced risk of mortality in cirrhotic patients, after full adjustment of confounding factors such as sex, age, smoking, alcohol, BMI, energy intake, etiology, Child Pugh and MELD score.

Consistent with the findings of the present study, previous studies have shown the relationship between dietary

total and vegetable protein intake and the reduction of the risk of mortality [13, 15], as well as the relationship between dietary animal protein intake and the increase of the risk of mortality [15] in various diseases. Also, replacing animal protein, especially processed red meat, with vegetable protein reduced the risk of mortality, which indicates the importance of the protein source [22]. An evaluation of a large cohort study in the United States of men and women with 16 years of follow-up presented that higher intake of plant protein decreased the risk of CVD and all-cause mortality in both sexes. Also, in this study, a significant inverse relationship was observed in





**Fig. 5** **A** Kaplan–Meier survival curve for death among cirrhotic patients stratified by tertiles of dietary protein intake (grams per kilogram body weight). The 4-year survival rate among patients across tertiles was 35%, 40%, 43%, respectively (log-rank test for homogeneity,  $P=0.004$ ). **B** Kaplan–Meier survival curve for death among cirrhotic patients stratified by tertiles of dairy protein intake (grams per day). The 4-year survival rate among patients across tertiles was 32%, 40%, 43%, respectively (log-rank test for homogeneity,  $P=0.001$ ). **C** Kaplan–Meier survival curve for death among cirrhotic patients stratified by tertiles of vegetable protein intake (grams per day). The 4-year survival rate among patients across tertiles was 35%, 42%, 41%, respectively (log-rank test for homogeneity,  $P=0.072$ ). **D** Kaplan–Meier survival curve for death among cirrhotic patients stratified by tertiles of animal protein intake (grams per day). The 4-year survival rate among patients across tertiles was 42%, 38%, 37%, respectively (log-rank test for homogeneity,  $P=0.296$ )

replacing red meat and egg protein with vegetable protein, including pasta, bread, and grains [23].

Vegetable protein may reduce systolic and diastolic blood pressure, improve lipoprotein and lipid profile and decrease insulin-like growth factor-1(IGF-1) [24–26]. In agreement with our study, in a large cohort study on cirrhotic patients waiting for liver transplant, it has been reported that low protein intake was prevalent and resulted in liver disease severity and worse clinical outcomes [27]. Also, it was independently associated with mortality and malnutrition [27]. Sam et al. reported that protein-energy malnutrition was prevalent in cirrhotic patients and was associated with higher in-hospital mortality [28]. Moreover, in another study, it has been

shown that in cirrhotic conditions, restricted dietary protein may stimulate protein catabolism and worsen hepatic encephalopathy [29]. In cirrhotic patients, protein requirement is higher than healthy population due to alterations in protein metabolism, PEM, muscle breakdown and protein-losing enteropathy caused by portal hypertension which may result in excessive intestinal protein losses [30]. Several factors connected low protein intake with cirrhosis-related mortality. First, protein is an important substance in human body necessary for carrying out vital body functions. Second, infection is a major cause of death in cirrhotic patients and low protein diet impairs both humoral and cell-mediated immunity and low dietary protein causes pro-inflammatory state [31].

Third, sufficient protein intake is necessary for muscle synthesis. In cirrhotic patients, glycogen reserves and synthetic capacity of liver is impaired, compensated by increased gluconeogenesis using amino acids of skeletal muscles [32].

The relationship between the dairy and vegetable protein intake and better nutritional and clinical status of cirrhotic patients has been already demonstrated [33]. Consistently, in a randomized cross-over trial, Bianchi et al. reported that in cirrhotic patients with chronic encephalopathy, vegetable protein could ameliorate nitrogen balance and mental state [34]. In addition to protein, vegetables are also rich in fiber. By inducing the mass of colon bacteria, fiber increases nitrogen consumption and reduces the incidence of hepatic encephalopathy [35].

Furthermore, the low level of plasma BCAAs including valine, leucine and isoleucine, is hallmark feature of cirrhosis patients [36]. Dairy and vegetable products are rich sources of BCAAs. Ruiz-Margain et al. reported that high-fiber, high-protein diet and BCAAs might increase muscle mass and prevent the increase in glucose and ammonium levels [37]. Another randomized control trial on cirrhotic patients showed that BCAAs supplementation improved prognosis, quality of life, nutritional status and albumin synthesis [12]. BCAAs activate mTOR signaling pathway which stimulates synthesis of muscle protein and albumin and regenerates liver cells [36].

Investigating the association of protein intake, separated by source, with the risk of cirrhosis-related mortality for the first time is one of the strengths of a current cohort study. In addition, adjusting potential confounders increased the reliability of the present study. The present study has limitations that should be considered, including a relatively small study population, inevitable recall bias using food frequency questionnaire (FFQ) and missing of about 15% of enrolled patients.

## Conclusion

In conclusion, we found a significant reverse association between total and dairy protein intake and a significant direct association between animal protein intakes with cirrhosis-related mortality. Further studies are recommended to evaluate effectiveness and appropriate amount of total, dairy, vegetable and animal protein in cirrhotic patients.

## Abbreviations

|       |   |
|-------|---|
| HR    | Hazard ratio  |
| CI    | Confidence intervals                                  |
| NAFLD | Non-alcoholic fatty liver disease                     |
| PEM   | Protein energy malnutrition                           |
| ESPEN | European Society of Clinical Nutrition and Metabolism |
| BCAA  | Branched chain amino acids                            |

|        |   |
|--------|---|
| NNFTRI | National nutrition and Food Technology Research Institute |
| FFQ    | Food frequency questionnaire                              |
| USDA   | The United States Department of Agriculture               |
| FCT    | Food composition table                                    |
| SGA    | Subjective global assessment tool                         |
| MELD   | Model for end-stage liver disease                         |
| ANOVA  | One-way analysis of variance                              |
| BMI    | Body mass index   |
| LTR    | Likelihood ratio test                                     |
| SPSS   | Statistical Package Software for Social Science           |
| IGF-1  | Insulin-like growth factor-1                              |

## Acknowledgements

Authors have no acknowledgments to declare.

## Authors' contributions

Conceptualization, ZY; Formal analysis, ZY; Methodology, SA, FP, SK, BH and MSF; Project administration, GD and AH; Writing – original draft, ANT, GD and As; Writing – review & editing, ZY and AH. All authors read and approved the final version of this manuscript.

## Funding

No Funding.

## Availability of data and materials

The datasets analyzed in the current study are available from the corresponding author on reasonable request.

## Declarations

### Ethics approval and consent to participate

Informed written consent was obtained from participants. All procedures performed in studies involving human participants adhered to the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

### Consent for publication

Not applicable.

### Competing interests

The authors declare no competing interests.

Received: 1 January 2023 Accepted: 24 May 2023

Published online: 03 July 2023

## References

- Rowe IA. Lessons from epidemiology: the burden of liver disease. *Dig Dis.* 2017;35(4):304–9.
- Anushiravani A, Sepanlou SG. Burden of liver diseases: a review from Iran. *Middle East J Dig Dis.* 2019;11(4):189.
- Yao CK, Fung J, Chu NHS, Tan VPY. Dietary interventions in liver cirrhosis. *J Clin Gastroenterol.* 2018;52(8):663–73.
- Dawood RM, El-Meguid MA, Salum GM, El Awady MK. Key Players of Hepatic Fibrosis. *J Interferon Cytokine Res.* 2020;40(10):472–89.
- Garcia-Tsao G, Friedman S, Iredale J, Pinzani M. Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosis. *Hepatology (Baltimore, MD).* 2010;51(4):1445.
- Juakiem W, Torres DM, Harrison SA. Nutrition in cirrhosis and chronic liver disease. *Clin Liver Dis.* 2014;18(1):179–90.
- Ishikawa T, Imai M, Ko M, Sato H, Nozawa Y, Sano T, et al. Evaluation of the branched-chain amino acid-to-tyrosine ratio prior to treatment as a prognostic predictor in patients with liver cirrhosis. *Oncotarget.* 2017;8(45):79480.
- Urata Y, Okita K, Korenaga K, Uchida K, Yamasaki T, Sakaida I. The effect of supplementation with branched-chain amino acids in patients with liver cirrhosis. *Hepatol Res.* 2007;37(7):510–6.

9. Plauth M, Merli M, Kondrup J, Weimann A, Ferenci P, Müller M, et al. ESPEN guidelines for nutrition in liver disease and transplantation. *Clin Nutr*. 1997;16(2):43–55.
10. Moriawaki H, Miwa Y, Tajika M, Kato M, Fukushima H, Shiraki M. Branched-chain amino acids as a protein-and energy-source in liver cirrhosis. *Biochem Biophys Res Commun*. 2004;313(2):405–9.
11. Holeček M. Branched-chain amino acid supplementation in treatment of liver cirrhosis: updated views on how to attenuate their harmful effects on cataplerosis and ammonia formation. *Nutrition*. 2017;41:80–5.
12. Muto Y, Sato S, Watanabe A, Moriawaki H, Suzuki K, Kato A, et al. Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. *Clin Gastroenterol Hepatol*. 2005;3(7):705–13.
13. Shinaberger CS, Kilpatrick RD, Regidor DL, McAllister CJ, Greenland S, Kopple JD, et al. Longitudinal associations between dietary protein intake and survival in hemodialysis patients. *Am J Kidney Dis*. 2006;48(1):37–49.
14. Fappi A, Mittendorf B. Dietary protein intake and obesity-associated cardiometabolic function. *Curr Opin Clin Nutr Metab Care*. 2020;23(6):380.
15. Song M, Fung TT, Hu FB, Willett WC, Longo VD, Chan AT, et al. Association of animal and plant protein intake with all-cause and cause-specific mortality. *JAMA Intern Med*. 2016;176(10):1453–63.
16. Mirmiran P, Esfahani FH, Mehrabi Y, Hedayati M, Azizi F. Reliability and relative validity of an FFQ for nutrients in the Tehran lipid and glucose study. *Public Health Nutr*. 2010;13(5):654–62.
17. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, Ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. *Hepatology*. 2000;31(4):864–71.
18. Yang Y, Zhao L-G, Wu Q-J, Ma X, Xiang Y-B. Association between dietary fiber and lower risk of all-cause mortality: a meta-analysis of cohort studies. *Am J Epidemiol*. 2015;181(2):83–91.
19. Detsky AS, Baker J, Johnston N, Whittaker S, Mendelson R, Jeejeebhoy K. What is subjective global assessment of nutritional status? *J Parenter Enter Nutr*. 1987;11(1):8–13.
20. Chen LK, Liu LK, Woo J, Assantachai P, Auyeung T-W, Bahyah KS, et al. Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia. *J Am Med Dir Assoc*. 2014;15(2):95–101.
21. Clark BC, Manini TM. What is dynapenia? *Nutrition*. 2012;28(5):495–503.
22. Tharrey M, Mariotti F, Mashchak A, Barbillon P, Delattre M, Fraser GE. Patterns of plant and animal protein intake are strongly associated with cardiovascular mortality: the Adventist Health Study-2 cohort. *Int J Epidemiol*. 2018;47(5):1603–12.
23. Huang J, Liao LM, Weinstein SJ, Sinha R, Graubard BI, Albanes D. Association between plant and animal protein intake and overall and cause-specific mortality. *JAMA Intern Med*. 2020;180(9):1173–84.
24. Chalvon-Demersay T, Azzout-Marniche D, Arfsten J, Egli L, Gaudichon C, Karagounis LG, et al. A systematic review of the effects of plant compared with animal protein sources on features of metabolic syndrome. *J Nutr*. 2017;147(3):281–92.
25. Holmes MD, Pollak MN, Willett WC, Hankinson SE. Dietary correlates of plasma insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations. *Cancer Epidemiol Biomarkers Prev*. 2002;11(9):852–61.
26. Allen NE, Appleby PN, Davey GK, Kaaks R, Rinaldi S, Key TJ. The associations of diet with serum insulin-like growth factor I and its main binding proteins in 292 women meat-eaters, vegetarians, and vegans. *Cancer Epidemiol Biomarkers Prev*. 2002;11(11):1441–8.
27. Ney M, Abralde JG, Ma M, Belland D, Harvey A, Robbins S, et al. Insufficient protein intake is associated with increased mortality in 630 patients with cirrhosis awaiting liver transplantation. *Nutr Clin Pract*. 2015;30(4):530–6.
28. Sam J, Nguyen GC. Protein-calorie malnutrition as a prognostic indicator of mortality among patients hospitalized with cirrhosis and portal hypertension. *Liver Int*. 2009;29(9):1396–402.
29. Córdoba J, López-Hellín J, Planas M, Sabin P, Sanpedro F, Castro F, et al. Normal protein diet for episodic hepatic encephalopathy: results of a randomized study. *J Hepatol*. 2004;41(1):38–43.
30. Charlton MR. Protein metabolism and liver disease. *Baillieres Clin Endocrinol Metab*. 1996;10(4):617–35.
31. Ling P-R, Bistrian BR. Comparison of the effects of food versus protein restriction on selected nutritional and inflammatory markers in rats. *Metabolism*. 2009;58(6):835–42.
32. Tsiaousi ET, Hatzitolios AI, Trygonis SK, Savopoulos CG. Malnutrition in end stage liver disease: recommendations and nutritional support. *J Gastroenterol Hepatol*. 2008;23(4):527–33.
33. Pashayee-Khamene F, Kord-Varkaneh H, Saber-Firoozi M, Hatami B, Rashidkhani B, Hekmatdoost A. Dietary protein sources and disease severity, malnutrition and anthropometric measurements in cirrhotic patients. *Gastroenterol Hepatol Bed Bench*. 2019;12(2):143.
34. Bianchi GP, Marchesini G, Fabbri A, Rondelli A, Bugianesi E, Zoli M, et al. Vegetable versus animal protein diet in cirrhotic patients with chronic encephalopathy. A randomized cross-over comparison. *J Intern Med*. 1993;233(5):385–92.
35. Amodio P, Caregaro L, Pettenó E, Marcon M, DelPiccolo F, Gatta A. Vegetarian diets in hepatic encephalopathy: facts or fantasies? *Dig Liver Dis*. 2001;33(6):492–500.
36. Ooi P, Gilmour S, Yap J, Mager D. Effects of branched chain amino acid supplementation on patient care outcomes in adults and children with liver cirrhosis: a systematic review. *Clin Nutr ESPEN*. 2018;28:41–51.
37. Ruiz-Margáin A, Macías-Rodríguez R, Ríos-Torres S, Román-Calleja B, Méndez-Guerrero O, Rodríguez-Córdova P, et al. Effect of a high-protein, high-fiber diet plus supplementation with branched-chain amino acids on the nutritional status of patients with cirrhosis. *Revista de Gastroenterol Méx (English Edition)*. 2018;83(1):9–15.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

